No products in the cart.
Pre-made Inotuzumab Ozogamicin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-868
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Inotuzumab Ozogamicin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[1][2]
| Products Name (INN Index) | Pre-Made Inotuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate |
|---|---|
| INN Name | inotuzumab ozogamicin |
| Target | CD22 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 – kappa |
| VD LC | IgG4 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Wyeth Pharmaceuticals (Madison NJ USA) / Pfizer (New York NY USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
Previous slide
Next slide
